PTC THERAPEUTICS, INC. — Form 8-K
Filed September 21, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 72/100
What the filing says
PTC Therapeutics completed acquisition of ST-920 (isaralgagene civaparvovec), a one-time AAV gene therapy for Fabry disease, from Sangamo Therapeutics. Rolling BLA submission to FDA expected Q4 2026. ST-920 has Orphan Drug, Fast Track, and RMAT designations from FDA. Specific acquisition price not disclosed in filing.
Why this rating
Major pipeline addition for $3.4B company; BLA-stage asset with regulatory designations reduces development risk; gene therapy addresses large unmet need in rare disease. Timing and valuation undisclosed limits certainty.
Tradability signal
NO TRADE
No trade: positive news with only +0.2% moved so far — good news prices in within seconds and long-side continuation has shown no measured edge (this cell: -0.54% over 4 hrs, n=45). (Filing arrived outside market hours — evaluated at the next open with a live quote.)
Derived from this site's own measured outcomes + live price/liquidity at analysis time. An experiment, not investment advice.
Price action (we called it positive)
before filing · preread $65.26 ▲ 0.00% | at our read · unknown $65.26 | +10 min · unknown $65.89 ▲ 0.97% | +30 min · unknown $66.03 ▲ 1.19% | +1 hr · unknown $65.96 ▲ 1.07% | +4 hrs · unknown $65.72 ▲ 0.70% |
The stock had already moved +0.00% between hitting EDGAR and our read finishing — deltas above are measured from our read.
Quotes via Yahoo Finance at capture time; for filings arriving outside market hours the clock starts at the next open. Not investment advice. How accurate are our calls? →
See more from September 21, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.